Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics by Hollander, J.G. (Jan) den et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/98/$04.0010
Apr. 1998, p. 744–748 Vol. 42, No. 4
Copyright © 1998, American Society for Microbiology
Use of Pharmacodynamic Parameters To Predict Efficacy of
Combination Therapy by Using Fractional Inhibitory
Concentration Kinetics
JAN G. DEN HOLLANDER,1,2* JOHAN W. MOUTON,1 AND HENRI A. VERBRUGH1
Department of Medical Microbiology and Infectious Diseases, University Hospital Rotterdam Dijkzigt,1
and Department of Internal Medicine, Zuiderziekenhuis,2 Rotterdam, The Netherlands
Received 17 April 1997/Returned for modification 16 October 1997/Accepted 5 January 1998
Combination therapy with antimicrobial agents can be used against bacteria that have reduced susceptibil-
ities to single agents. We studied various tobramycin and ceftazidime dosing regimens against four resistant
Pseudomonas aeruginosa strains in an in vitro pharmacokinetic model to determine the usability of combination
therapy for the treatment of infections due to resistant bacterial strains. For the selection of an optimal dosing
regimen it is necessary to determine which pharmacodynamic parameter best predicts efficacy during combi-
nation therapy and to find a simple method for susceptibility testing. An easy-to-use, previously described E-
test method was evaluated as a test for susceptibility to combination therapy. That test resulted in a MICcombi,
which is the MIC of, for example, tobramycin in the presence of ceftazidime. By dividing the tobramycin and
ceftazidime concentration by the MICcombi at each time point during the dosing interval, fractional inhibitory
concentration (FIC) curves were constructed, and from these curves new pharmacodynamic parameters for
combination therapy were calculated (i.e., AUCcombi, Cmax-combi, T>MIC-combi, and T>FICi, where AUCcombi,
Cmax-combi, T>MIC-combi, and T>FICi are the area under the FICcombi curve, the peak concentration of FICcombi,
the time that the concentration of the combination is above the MICcombi, and the time above the FIC index,
respectively). By stepwise multilinear regression analysis, the pharmacodynamic parameter T>FICi proved to
be the best predictor of therapeutic efficacy during combination therapy with tobramycin and ceftazidime (R2 5
0.6821; P < 0.01). We conclude that for combination therapy with tobramycin and ceftazidime the T>FICi is the
parameter best predictive of efficacy and that the E-test for susceptibility testing of combination therapy gives
promising results. These new pharmacodynamic parameters for combination therapy promise to provide better
insight into the rationale behind combination therapy.
In the last decade three important pharmacodynamic pa-
rameters which correlate well with therapeutic efficacy in
in vitro as well as in animal models have been described. These
parameters differentiate between groups of antimicrobial
agents with diverse mechanisms of action. For instance, the
efficacies of b-lactam antibiotics and erythromycin correlate
best with the time that the levels in serum exceed the MIC
(T.MIC), while for aminoglycosides the area under the con-
centration-time curve (AUC) best predicts therapeutic efficacy
(32). Furthermore, aminoglycosides display concentration-de-
pendent killing in vitro (9, 31) and in vivo (16), indicating the
importance of the third pharmacokinetic parameter, i.e., the
peak concentration (Cmax). On the basis of these observations
new dosing regimens for these antimicrobial agents are now
being used, including aminoglycoside dosing regimens that
were changed from thrice daily to once daily (22, 28).
However, all these pharmacodynamic studies used single
agents and the pharmacodynamic parameters for combination
therapy are still lacking. Parameters which have been used to
show interactions during combination therapy are the frac-
tional inhibitory concentration (FIC) indices (FICis), derived
from checkerboard titrations (2, 3, 6, 11, 14, 15, 24). Alterna-
tively, a significant change in the killing rates observed in
time-kill experiments has been used (7, 13, 27). Recently, a
computer model, the MacSynergy program, has been used to
indicate synergism (8). This method provides us with a rating
of synergism expressed as the maximum effect of the drug
combination. Although this method is much more accurate in
predicting the synergistic effect of two drugs, it does not indi-
cate the pharmacodynamic parameters which predict efficacy.
Unfortunately, the results of the various studies are discor-
dant with the results of checkerboard titrations, the results of
time-kill experiments, and clinical outcome (5, 23, 24). In spite
of the numerous studies evaluating combination therapy, no
pharmacodynamic parameters that can accurately predict the
therapeutic efficacy of combination therapy have been found.
One of the most important reasons is that all methods de-
scribed above were based on efficacy at static drug concentra-
tions, while in vivo the concentrations decline over time.
The purpose of the present study was to search for a phar-
macodynamic parameter that may predict the therapeutic ef-
ficacy of combination therapy. For this purpose, several tobra-
mycin and ceftazidime dosing regimens were simulated in an
vitro pharmacokinetic model to study their effect on resistant
Pseudomonas aeruginosa strains. A simplified version of the
checkerboard titration, i.e., an E-test for combination therapy
(33), was also included.
(This paper was presented at the 37th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, Toronto,
Ontario, Canada, 28 September to 1 October 1997 [7a].)
MATERIALS AND METHODS
Theoretical approach. To obtain pharmacodynamic parameters for combina-
tion therapy that are comparable to the AUC, Cmax, and T.MIC for mono-
therapy, it is not possible to simply add the values of the pharmacodynamic
parameters for the different antibiotics. We therefore introduce here new phar-
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macodynamic parameters for combination therapy, i.e., the AUC
combi
, Cmax-combi,
T.MIC-combi, and T.FICi (the area under the FICcombi curve, the peak concen-
tration of FICcombi, the time that the concentration of the combination is above
the MICcombi, and the time above the FICi, respectively), which are based on FIC
curves and which are explained below. These curves were calculated as follows.
The FIC used in the checkerboard titration to calculate FICi is defined as the
concentration of antibiotic Y1 (in the presence of drug Y2) in a well (CW) di-
vided by the MIC of that drug for the strain (2, 3, 10) and is expressed as FICY 5
CW/MIC (equation 1). The FICi is then calculated as S(FICY1 1 FICY2)/n
(equation 2), where Y1 and Y2 are the two antibiotics, respectively, and n is the
number of wells used to calculate the sum of the FICs.
However, in checkerboard titrations the concentrations of the antibiotics are
constant in each well. During the dosing regimens in the in vitro model these
concentrations change over time during the dosing interval. Therefore, we sim-
ulated the concentration-time curves for the individual drugs. At time intervals
of 0.1 h a FIC at time t (FICt) was calculated for the concentration at that time
(Ct) by equation 1 and was comparable to the checkerboard titration as FICt
5 Ct/MIC (equation 3), resulting in a FIC curve over time.
However, equation 3 uses the MIC during exposure to a single agent. During
combination therapy it is likely that the MIC of each drug changes in the
presence of the other drug; i.e., the MIC decreases if the drugs are acting
synergistically. A recently described method (33) for susceptibility testing during
combination therapy is based on the E-test and has provided us with a new
method of determining the MIC of tobramycin in the presence of ceftazidime
(and vice versa), which is further called the MICcombi and which could be used
as a parameter for describing the susceptibility of a strain during combination
therapy. To obtain FIC curves for combination therapy, the concentrations at
each time point were divided by the MICcombi rather than the MIC, and these are
expressed as: FICt,combi 5 Ct/MICcombi (equation 4). The FICcombi curve was
then calculated by adding the FIC of tobramycin and the FIC of ceftazidime at
the same time point in the concentration-time curves, expressed as FICcombi 5
FIC
t, tobra
1 FICt, cefta (equation 5), where FICt, tobra and FICt, cefa are FICts
for tobramycin and ceftazidime, respectively, resulting in FICcombi curves
against time. From these FICcombi curves the new pharmacodynamic param-
eters AUCcombi, Cmax-combi, and T.FICi were calculated. The T.MIC-combi is the
time that the concentration of one or both of the antibiotics is above the
MICcombi. The time above the MICcombi (T.MIC-combi) was calculated from the
concentration-time curves for the different antibiotics by the same method
normally used to calculate the time above the MIC, but for T.MIC-combi the
MICcombi was used.
Bacterial strains, antibiotics, and media. Four nonmucoid Pseudomonas
aeruginosa strains which were isolated from the sputa of cystic fibrosis patients
(CF 133, CF 5706, CF 5846, and CF 5879, respectively) were used in this study.
The MICs of tobramycin (Eli Lilly & Company, Nieuwegein, The Netherlands)
and ceftazidime (Glaxo, Zeist, The Netherlands) were determined by a standard
macrodilution method (21) in Mueller-Hinton broth (Difco, Amsterdam, The
Netherlands) supplemented with Ca21 (25 mg/liter) and Mg21 (12.5 mg/liter)
(MHBs), as well as by the E-test technique (AB-Biodisk, Solna, Sweden) with
Mueller-Hinton agar (Difco) supplemented with Ca21 (25 mg/liter) and Mg21
(12.5 mg/liter). All strains were resistant or intermediately susceptible to both
tobramycin and ceftazidime. All samples used for determination of CFU counts
were plated onto Trypticase soy agar (Oxoid, Basingstoke, Hampshire, England).
The mechanism of resistance for aminoglycosides was determined as described
by Van de Klundert et al. (29) by identification of the aminoglycoside-modifying
enzymes involved. The mechanism of resistance for b-lactam antibiotics was
determined by semiquantitative susceptibility testing, substrate analysis, and iso-
electric focusing of the extracted b-lactamase (30).
FICis. FICis were determined both by a modified macrodilution checkerboard
macrotitration technique (14) and by an E-test technique (33) (Fig. 1). The FICs
and FICis were calculated as usual (2, 10). Synergism by the modified macrodi-
lution checkerboard technique was defined as a FICi of #0.8 and indifference
was defined as a FICi of between 0.8 and 4.0 (15). For the E-test method
synergism was defined as a FICi of #0.5 and indifference was defined as a FICi
of between $0.5 and #4.0, comparable to the definitions used for twofold
dilution checkerboard titrations (27).
In vitro pharmacokinetic model. The pharmacokinetic model used in this
study was previously described in detail (20). Briefly, a two-compartment model
consisting of one central compartment and four peripheral compartments (dis-
posable dialyzer units, model ST23; Baxter, Utrecht, The Netherlands) was used
to expose the bacteria in the peripheral compartments to changing antibiotic
concentrations that mimic the pharmacokinetics in humans. At time zero the
peripheral compartments were inoculated with a logarithmic-phase culture of
P. aeruginosa of approximately 5 3 105 CFU/ml, with a different strain used in
each peripheral compartment. Control growth in the model was determined in
the same way but without the addition of antibiotics.
Dosing regimens. Fourteen different dosing regimens were applied, with peak
concentrations of 32, 16, 8, and 4 mg/liter for tobramycin and 128, 64, and 32
mg/liter for ceftazidime. The drugs were given simultaneously (i.e., tobramycin at
time zero followed by ceftazidime at 20 min, or vice versa) or nonsimultaneously
(i.e., tobramycin at time zero and ceftazidime at 4 h, or vice versa). During the
simultaneous dosing regimens tobramycin was given thrice daily or once daily.
The half-lives of both tobramycin and ceftazidime was adjusted to 2 h. Samples
were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 9, 12, 16, and 24 h. The samples were
immediately washed (twice) with cold phosphate-buffered saline, and 0.1-ml
samples were plated onto Trypticase soy agar plates (limit of detection, 10
CFU/ml). Samples were assayed for tobramycin by a fluorescence polarization
immunoassay with a TDxFLx instrument (Abbott Diagnostic Division, Amstel-
veen, The Netherlands) and for ceftazidime by high-performance liquid chro-
matography, as described earlier (19). The lower limits of sensitivity of both
assays were 0.5 mg/liter. The between-day, between-sample variation was less
than 7%.
Data analysis. The pharmacodynamic parameters AUC, Cmax, and T.MIC for
the individual drugs were calculated from simulated concentration-time curves
by the equation for an open-compartment model after extravascular administra-
tion (25). The area under the killing curve from time zero to 24 h (AUKC0–24)
was calculated by using the trapezoidal rule on logarithmically transformed,
experimentally obtained datum points.
Statistical analysis. The peak and trough concentrations and half-lives of the
antibiotics during the different experiments were compared by using a two-way
analysis of variance and Tukey’s test for multiple comparison of significance with
the Instat 2 computer package (11). A P value of #0.05 (two tailed) was con-
sidered significant.
The correlation between the four pharmacodynamic parameters (AUCcombi,
Cmax-combi, T.MIC-combi, and T.FICi) and efficacy (i.e., change in CFU per mil-
liliter 5 log10 CFU per milliliter at 24 h 2 log10 CFU per milliliter at time zero
or AUKC0–24) were calculated by stepwise multilinear regression analysis with
the SAS computer package (26). The F test was used to choose the best model.
RESULTS
MICs and FICs. The MICs and the MICcombis of tobramycin
and ceftazidime for the four strains were determined by the
E-test method and are presented in Table 1. Also presented in
Table 1 are the FICis determined by the E-test and a modified
macrodilution checkerboard titration method. The MICs de-
termined by a macrodilution standard assay, were not signifi-
cantly different from those determined by the E-test (data not
shown). The calculated values of the FICis obtained by using
the MICs obtained by the macrodilution assay differed some-
FIG. 1. Schematic diagram of the E-test combination therapy susceptibility
test described by White et al. (33).
TABLE 1. Analysis of susceptibility tests showing synergy between
tobramycin and ceftazidime against four P. aeruginosa strains
Strain
MIC
(mg/liter)a
MICcombi
(mg/liter)b FICi
c
Tobra-
mycin
Cef-
tazidime
Tobra-
mycin
Cef-
tazidime E-test
Macro-
dilution
method
CF 133 32 64 6 16 0.44 0.37
CF 5706 128 16 32 6 0.63 0.68
CF 5846 12 512 6 128 0.75 0.67
CF 5879 16 512 1.5 8 0.10 0.39
a Determined by E-test.
b Determined by combination E-test.
c Calculated; see Materials and Methods.
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what from those obtained by using the MICs obtained by the
E-test, but for all four strains the two calculations resulted in
the same conclusion, i.e., that there is synergism or indiffer-
ence.
Mechanism of resistance. All four strains produced a b-lac-
tamase which was identified as a stably depressed, chromo-
somally encoded class I b-lactamase (4). The mechanism of
resistance for tobramycin was due to the production of several
aminoglycoside modifying enzymes, which were identified as
AAC(69)-II and APH(39) for strains CF 133 and CF 5706,
APH(39) for strain CF 5846, and ANT(20) and APH(39) for
strain CF 5879.
Pharmacokinetics and pharmacodynamics of combination
therapy. The peak and trough concentrations and the half-lives
did not differ significantly between the experiments and were
comparable to the values targeted for these experiments. On
the basis of these data, the concentration-time curves and the
FICcombi curves were simulated. An example of a simulation of
the concentration-versus-time curves for tobramycin and ceft-
azidime during a nonsimultaneous dosing regimen and the
calculated FICcombi curve for this particular regimen are pre-
sented in Fig. 2. This combination therapy regimen results in
FICcombi curves with values that cycle between 0.1 and 1.1 from
0 to 24 h.
The correlation between the values of the pharmaco-
dynamic parameters (AUCcombi, Cmax-combi, T.MIC-combi,
and T.MIC-combi) for all dosing regimens and the Dlog10
CFU per milliliter are presented in Fig. 3. The T.FICi and
the T.MIC-combi showed a linear relation with efficacy, and
AUCcombi and Cmax-combi showed a log-linear relation with
efficacy. The correlation between the four pharmacodynamic
parameters and the AUKC0–24 was less than that between the
four parameters and the Dlog10 CFU per milliliter over 24 h
but showed the same trend for the importance of the param-
eters (Table 2). The most important parameter predicting ef-
FIG. 2. Representative concentration-versus-time curves for ceftazidime (A)
and tobramycin (B) and the corresponding FICcombi-versus-time curve (C) dur-
ing one combination therapy regimen. In this case the FICcombi curve, the MIC,
and the MICcombi are based on data for P. aeruginosa CF 133. Breakpoints are
according to NCCLS guidelines (19).
FIG. 3. Correlation between pharmacodynamic parameters for combination therapy and efficacy, expressed as Dlog10CFU per milliliter.
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ficacy was T.FICi, as shown by the coefficient of determination
(R2) for all four strains and all regimens together, which was
0.6821. For strain CF 133 enough data were available for the
calculation of R2 for the individual parameters. The R2 values
for this strain showed the same trend as the R2 values for the
four strains but were higher. For the most important parame-
ter, T.FICi, R
2 was 0.7604 (data not shown in Table 2).
DISCUSSION
We studied various dosing regimens for combination ther-
apy to determine whether combination therapy may be effica-
cious against resistant strains and, if so, to determine what
pharmacodynamic parameter(s) may best predict efficacy. Re-
cently, we showed that therapy with a combination of tobra-
mycin and ceftazidime was effective against a P. aeruginosa
strain resistant to both drugs (7). The use of combination
therapy that has a synergistic or additive effect may thus be a
strategy for treating patients with infections due to multiply
resistant strains. For the selection of the optimal dosing regi-
mens for combination therapy, two important factors should be
known. First, a method which indicates the susceptibility of a
bacterial strain during combination therapy is needed, and
second, the pharmacodynamic parameter(s) that predicts effi-
cacy should be elucidated. In this study of combination therapy
of tobramycin with ceftazidime against resistant Pseudomonas
strains, both objectives were goals.
Recently, White et al. (33) developed an easy method of
calculating the FICi from MIC data obtained with E-test strips.
By their method, it is possible to determine the MIC of tobra-
mycin in the presence of ceftazidime and vice versa, thus pro-
viding a MICcombi of each drug. If a combination of drugs with
synergistic or additive activity is used, a decrease in the MIC of
the combination compared to the MIC of the individual drug
is seen. To evaluate whether a strain was susceptible to tobra-
mycin during combination therapy, the breakpoints for the
individual drugs were used initially. Thus, it was shown that
P. aeruginosa CF 133, which was resistant to both tobramycin
and ceftazidime according to the breakpoints of the National
Committee for Clinical Laboratory Standards (NCCLS) (21),
appears to be susceptible to both antibiotics if they are used in
combination (i.e., the MICcombi was below the NCCLS break-
point for monotherapy). This observation explains our earlier
finding that this strain was killed during an in vitro simulation
of the combination therapy regimens commonly used in cystic
fibrosis patients suffering from P. aeruginosa infections of the
lung (7). For all four strains the MICcombis were lower than the
MICs (Table 1), and as was to be expected, all strains were
killed in the in vitro pharmacokinetic model if combination
therapy with tobramycin and ceftazidime was simulated. In-
deed, by the various regimens, all strains were killed to some
extent as measured by the Dlog10 CFU per milliliter at 24 h.
Compared to the NCCLS susceptibility breakpoint for tobra-
mycin or ceftazidime (21), the MICcombis for two strains
(strains CF 133 and CF 5879) were below these breakpoints for
both antibiotics, while for the other two strains one of either of
the two MICcombis was below the NCCLS breakpoint (Table
1). This may explain why all four strains behaved as if they were
susceptible during time-kill experiments in the pharmacoki-
netic model, since they were susceptible to at least one of the
two antibiotics. Thus, it may be concluded that if the MICcombi
of at least one of the drugs used during combination therapy is
below the NCCLS breakpoint, it is to be expected that the
microorganism will be killed during combination therapy.
Since no susceptibility breakpoints for combination therapy
have been published, the data presented in this report suggest
that if the MICcombi is lower than the NCCLS breakpoints
(based on monotherapy regimens), the MICcombi is a reason-
able predictor of susceptibility during combination therapy.
These observations indicate only that, at least for the four
strains used, the susceptibility during combination therapy can
be predicted by the E-test method (33). However, this is only
based on the results for four strains, and it is therefore too
preliminary to introduce this test as a new standard for testing
susceptibility to combination therapy. It only suggests a new
line of research that seems worthy of examination. Further in
vitro and in vivo experiments are needed to further confirm
this or to develop new breakpoints for combination therapy.
A similar relation between in vitro data and the in vivo
susceptibility of a resistant strain was shown by Mordenti et al.
(18). They compared data derived from standard in vitro time-
kill experiments and similar tests in an animal model combin-
ing amikacin with ticarcillin. They showed that the lowest con-
centration of the drugs that was still synergistic in standard
time-kill experiments predicted whether a resistant strain
would be susceptible during combination therapy. However,
the use of time-kill experiments is far more laborious than the
use of the E-test method recently described by White et al.
(33).
To study the pharmacodynamic principles of combination
therapy in a way similar to that used for monotherapy (31, 32),
new parameters are needed. Such new parameters (AUCcombi,
Cmax-combi, and T.FICi) obtained with the use of FIC curves
and a fourth parameter (i.e., T.MIC-combi) that could be esti-
mated from the concentration-time curves were proposed in
this report. A stepwise linear regression analysis of these four
new pharmacodynamic parameters for combination therapy
revealed that T.FICi is the most important parameter that
predicts the efficacy (P , 0.01) of tobramycin and ceftazidime
combinations against P. aeruginosa. For all four strains to-
gether this parameter showed a reasonable correlation with the
Dlog10 CFU per milliliter at 24 h (R
2 5 0.6821); an even better
correlation was found for strain CF 133 alone (R2 5 0.7604).
The fact that the T.FICi is important may explain why the use
of nonsimultaneous dosing regimens will result in greater kill-
ing than that from simultaneous dosing of these agents (1, 12,
17), since the nonsimultaneous dosing regimens provide longer
T.FICis compared to those provided by the simultaneous dos-
ing regimens. However, due to variability in the data these
correlations may seem overinterpreted, but the multilinear re-
gression analysis and the statistical tests show significant cor-
relations. Even though there is variability in the data, the
correlations between the four pharmacodynamic parameters
and efficacy suggest that all parameters are linked to efficacy,
and further research along these lines is needed to reveal the
right correlations for all kinds of combination therapy.
In conclusion, we described a simple method of determin-
ing the susceptibility of a strain during combination therapy
TABLE 2. Correlation between pharmacodynamic parameters
and efficacy during combination therapy
Pharmacodynamic
parameter
Range of
values tested
R2
Dlog10 CFU/ml
at 24 h AUKC0–24
a
AUCcombi (h) 0–230 0.5233 0.3070
Cmax-combi 0–25.5 0.5652 0.3929
T.MIC-combi (h) 0–23.9 0.5344 0.3520
T.FICi (h) 0–24 0.6821 0.5350
a AUKC0–24 calculated as log10 CFU z h/ml.
VOL. 42, 1998 PHARMACODYNAMICS IN COMBINATION THERAPY 747
and propose new pharmacodynamic parameters (AUCcombi,
Cmax-combi, T.FICi, and T.MIC-combi) which predict the efficacy
of the combination therapy; of these, T.FICi seems to be cor-
related best with the efficacy of combination therapy with
tobramycin and ceftazidime. The efficacies of other drug com-
binations may well be best predicted by other pharmacody-
namic parameters. Such knowledge would provide a rationale
for dosing regimens with combination therapy and may pro-
vide us with optimal dosing regimens for the treatment of
patients with infections caused by multiply resistant bacterial
strains.
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ADDENDUM
A stepwise description of the dynamic FIC curves is as fol-
lows.
(i) Determine the MICcombi for each drug and strain by the
method of White et al. (33).
(ii) Calculate the concentration-time profile for the drug
regimen, comparable to Fig. 2A and B.
(iii) Divide for each time point the actual drug concentration
by the MICcombi of that drug. Add the two FICs at that time
point and plot those against time. This results in the dynamic
FICcombi profile shown in Fig. 2C.
(iv) Use this FICcombi-versus-time profile to calculate three
new pharmacodynamic parameters: AUCcombi, Cmax-combi, and
T.FICi.
(v) Calculate the T.MIC-combi, which is the time during
which at least one of the drug concentrations is above the
MICcombi, from the two drug concentration-versus-time pro-
files (Figure 2A and B).
(vi) The therapeutic effect can be expressed as the Dlog CFU
per milliliter at 24 h and as the AUKC0–24.
(vii) Try to find a correlation between the pharmacodynamic
parameters for combination therapy and the therapeutic effect.
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